{"entity":{"id":"promega","kind":"company","name":"Promega","aka":[],"tldr":"Wisconsin life-science company whose OncoMate test for microsatellite instability is an FDA companion diagnostic for pembrolizumab.","summary":"Promega Corporation, the applicant on FDA records at Madison, Wisconsin, makes the OncoMate MSI Dx Analysis System, approved in November 2025 as the companion diagnostic for pembrolizumab with lenvatinib in microsatellite-stable endometrial carcinoma and in September 2026 for pembrolizumab in MSI-high solid tumours.","asOf":"2026-11-03","links":[{"label":"Official website","url":"https://www.promega.com"},{"label":"FDA PMA P250046","url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?id=P250046"}],"tags":[],"related":[],"cancers":["endometrial"],"sections":["diagnostics"],"technologies":["companion-diagnostic"],"targets":[],"drugs":["oncomate-msi-dx"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"hq":"Madison, WI","country":"US","companyType":"diagnostics","website":"https://www.promega.com","investors":[],"funding":[]},"route":"/companies/promega/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"}],"section":[{"id":"diagnostics","kind":"section","name":"Diagnostics & Biomarkers","route":"/fronts/diagnostics/"}],"technology":[{"id":"companion-diagnostic","kind":"technology","name":"Companion diagnostics","route":"/technologies/companion-diagnostic/"}],"drug":[{"id":"oncomate-msi-dx","kind":"drug","name":"OncoMate MSI Dx Analysis System","route":"/drugs/oncomate-msi-dx/"}]}}